Delowar Kobir Jibon
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Delowar Kobir Jibon has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
- Omar Faruqe
Department of Computer Science and Engineering, University of Rajshahi, Rajshahi, Bangladesh
2 shared publications - Anil Chandra Deb
Department of Genetic Engineering and Biotechnology, University of Rajshahi, Rajshahi, Bangladesh
1 shared publication - Aslam Ali
Department of Genetic Engineering and Biotechnology University of Rajshahi, Rajshahi 6205, Bangladesh
1 shared publication - Fahmida Khanom Alo1 shared publication
- Farzana Akter
Department of Genetic Engineering and Biotechnology University of Rajshahi, Rajshahi 6205, Bangladesh
1 shared publication - Kazi Md. Faisal Hoque
Molecular Biology and Protein Science Laboratory, Department of Genetic Engineering & Biotechnology, University of Rajshahi, Rajshahi-6205, Bangladesh
1 shared publication
Latest Publications
- Open Access
- 20 February 2026
- Published by Elsevier in SSRN Electronic Journal
Inhibitory efficacy and binding mode prediction of natural compounds against pathogenic factors of Alternaria solani: insights from AlphaFold, molecular simulations, and post-simulation analyses
Early blight disease, caused by the fungal pathogen Alternaria solani, is a significant threat to global crop production, particularly affecting widely cultivated crops such as potatoes and tomatoes. The emergence of fungicide resistance and growing environmental concerns have intensified the need for sustainable alternatives to conventional chemical fungicides. This study explores the potential of natural agents to combat A. solani by targeting two key effector proteins, AsCEP112 and AsCEP50, which play critical roles in the infection process. A comprehensive library of 608 natural compounds with known antifungal properties was evaluated using advanced computational approaches. Molecular docking simulation studies identified BR-xanthone A as a highly potent compound, demonstrating superior binding affinities to both the target proteins compared to reference fungicides (Strobilurin and Azoxystrobin). Additionally, Allicin with AsCEP50 and Alpha-mangostin with AsCEP112 exhibited promising binding energies. High-throughput molecular dynamics (MD) simulations assessed stability and interactions, with parameters such as RMSD, RMSF, Rg, SASA, and hydrogen bonds. Post-simulation analyses, including MM-PBSA, PCA, FEL, and PDF, further validated the stability nature of the ligand-protein complexes and revealed probable conformational changes. BR-xanthone A also displayed excellent bioactivity scores and fungicide-likeness, outperforming the reference compounds. This study highlights the potential of natural fungicides as sustainable and effective alternatives to traditional chemical treatments. The selected compound, BR-xanthone A, emerged as a strong candidate for developing next-generation fungicides by specifically targeting fungal virulence factors. The findings provide valuable insights for developing future eco-friendly fungus control agents and enhancing global food security in the face of fungal pathogen threats.
- 20 February 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessInhibitory efficacy and binding mode prediction of natural compounds against pathogenic factors of Alternaria solani: insights from AlphaFold, molecular simulations, and post-simulation analyses
Early blight disease, caused by the fungal pathogen Alternaria solani, is a significant threat to global crop production, particularly affecting widely cultivated crops such as potatoes and tomatoes. The emergence of fungicide resistance and growing environmental concerns have intensified the need for sustainable alternatives to conventional chemical fungicides. This study explores the potential of natural agents to combat A. solani by targeting two key effector proteins, AsCEP112 and AsCEP50, which play critical roles in the infection process. A comprehensive library of 608 natural compounds with known antifungal properties was evaluated using advanced computational approaches. Molecular docking simulation studies identified BR-xanthone A as a highly potent compound, demonstrating superior binding affinities to both the target proteins compared to reference fungicides (Strobilurin and Azoxystrobin). Additionally, Allicin with AsCEP50 and Alpha-mangostin with AsCEP112 exhibited promising binding energies. High-throughput molecular dynamics (MD) simulations assessed stability and interactions, with parameters such as RMSD, RMSF, Rg, SASA, and hydrogen bonds. Post-simulation analyses, including MM-PBSA, PCA, FEL, and PDF, further validated the stability nature of the ligand-protein complexes and revealed probable conformational changes. BR-xanthone A also displayed excellent bioactivity scores and fungicide-likeness, outperforming the reference compounds. This study highlights the potential of natural fungicides as sustainable and effective alternatives to traditional chemical treatments. The selected compound, BR-xanthone A, emerged as a strong candidate for developing next-generation fungicides by specifically targeting fungal virulence factors. The findings provide valuable insights for developing future eco-friendly fungus control agents and enhancing global food security in the face of fungal pathogen threats.
- Open Access
- 1 January 2024
- Published by Wiley in BioMed Research International
- Vol. 2024 (1) , 6810200
Integrated Gene Expression Data‐Driven Identification of Molecular Signatures, Prognostic Biomarkers, and Drug Targets for Glioblastoma
Glioblastoma (GBM) is a highly prevalent and deadly brain tumor with high mortality rates, especially among adults. Despite extensive research, the underlying mechanisms driving its progression remain poorly understood. Computational analysis offers a powerful approach to explore potential prognostic biomarkers, drug targets, and therapeutic agents for GBM. In this study, we utilized three gene expression datasets from the Gene Expression Omnibus (GEO) database to identify differentially expressed genes (DEGs) associated with GBM progression. Our goal was to uncover key molecular players implicated in GBM pathogenesis and potential avenues for targeted therapy. Analysis of the gene expression datasets revealed a total of 78 common DEGs that are potentially involved in GBM progression. Through further investigation, we identified nine hub DEGs that are highly interconnected in protein–protein interaction (PPI) networks, indicating their central role in GBM biology. Gene Ontology (GO) and pathway enrichment analyses provided insights into the biological processes and immunological pathways influenced by these DEGs. Among the nine identified DEGs, survival analysis demonstrated that increased expression of GMFG correlated with decreased patient survival rates in GBM, suggesting its potential as a prognostic biomarker and preventive target for GBM. Furthermore, molecular docking and ADMET analysis identified two compounds from the NIH clinical collection that showed promising interactions with the GMFG protein. Besides, a 100 nanosecond molecular dynamics (MD) simulation evaluated the conformational changes and the binding strength. Our study highlights the potential of GMFG as both a prognostic biomarker and a therapeutic target for GBM. The identification of GMFG and its associated pathways provides valuable insights into the molecular mechanisms driving GBM progression. Moreover, the identification of candidate compounds with potential interactions with GMFG offers exciting possibilities for targeted therapy development. However, further laboratory experiments are required to validate the role of GMFG in GBM pathogenesis and to assess the efficacy of potential therapeutic agents targeting this molecule.
- 1 January 2024
- Published by Wiley in BioMed Research International
- Vol. 2024 (1) , 6810200
Open AccessIntegrated Gene Expression Data‐Driven Identification of Molecular Signatures, Prognostic Biomarkers, and Drug Targets for Glioblastoma
Glioblastoma (GBM) is a highly prevalent and deadly brain tumor with high mortality rates, especially among adults. Despite extensive research, the underlying mechanisms driving its progression remain poorly understood. Computational analysis offers a powerful approach to explore potential prognostic biomarkers, drug targets, and therapeutic agents for GBM. In this study, we utilized three gene expression datasets from the Gene Expression Omnibus (GEO) database to identify differentially expressed genes (DEGs) associated with GBM progression. Our goal was to uncover key molecular players implicated in GBM pathogenesis and potential avenues for targeted therapy. Analysis of the gene expression datasets revealed a total of 78 common DEGs that are potentially involved in GBM progression. Through further investigation, we identified nine hub DEGs that are highly interconnected in protein–protein interaction (PPI) networks, indicating their central role in GBM biology. Gene Ontology (GO) and pathway enrichment analyses provided insights into the biological processes and immunological pathways influenced by these DEGs. Among the nine identified DEGs, survival analysis demonstrated that increased expression of GMFG correlated with decreased patient survival rates in GBM, suggesting its potential as a prognostic biomarker and preventive target for GBM. Furthermore, molecular docking and ADMET analysis identified two compounds from the NIH clinical collection that showed promising interactions with the GMFG protein. Besides, a 100 nanosecond molecular dynamics (MD) simulation evaluated the conformational changes and the binding strength. Our study highlights the potential of GMFG as both a prognostic biomarker and a therapeutic target for GBM. The identification of GMFG and its associated pathways provides valuable insights into the molecular mechanisms driving GBM progression. Moreover, the identification of candidate compounds with potential interactions with GMFG offers exciting possibilities for targeted therapy development. However, further laboratory experiments are required to validate the role of GMFG in GBM pathogenesis and to assess the efficacy of potential therapeutic agents targeting this molecule.